To be quite candid, I don't think anything Canada does has an impact on global R and D and innovation on a macro level. I suspect the same conversations probably took place back in the fifties and sixties, when Tommy Douglas was advocating medicare and a publicly funded health care system. I've heard lots of doomsday scenarios. I'm not aware of this particular study from the Chamber of Commerce, but at the end of the day, one would presume that if prices were lower, volume would go up—that's typically how supply and demand works—and more people would have access to the drugs.
Ultimately, it's a matter of finding a juste milieu between access and cost and price. That's where we think we're headed with these changes. That's taking into account value for money, by which I mean pharmacoeconomics or cost-effectiveness, and overall affordability in terms of the market size of the drug and its impact on the budgets of public and private drug plans.
I'm not sure if I answered your question.